| 0.8657 -0.008 (-0.88%) | 01-27 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.23 | 1-year : | 1.44 |
| Resists | First : | 1.05 | Second : | 1.23 |
| Pivot price | 0.77  |
|||
| Supports | First : | 0.77 | Second : | 0.6 |
| MAs | MA(5) : | 0.86 | MA(20) : | 0.77 |
| MA(100) : | 1.03 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.4 | D(3) : | 71.4 |
| RSI | RSI(14): 54.2 | |||
| 52-week | High : | 3.73 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZIOP ] has closed below upper band by 22.6%. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Wed, 26 Jan 2022
Ziopharm hopes to put a rough year behind it with rebrand to Alaunos Therapeutics - Fierce Biotech
Mon, 30 Aug 2021
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions - GlobeNewswire
Tue, 17 Nov 2020
Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer - Yahoo Finance
Tue, 22 Sep 2020
Ziopharm Oncology Appoints Kevin Buchi to Board - citybiz
Wed, 18 Oct 2017
What to do with your Ziopharm (ZIOP) shares - Nanalyze
Thu, 28 Sep 2017
ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 216 (M) |
| Held by Insiders | 1.7244e+008 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 32,730 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.566e+007 |
| EPS Est Next Qtrly | -0.15 |
| EPS Est This Year | -0.57 |
| EPS Est Next Year | -0.61 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -22 % |
| Return on Assets (ttm) | 103.5 % |
| Return on Equity (ttm) | -39.4 % |
| Qtrly Rev. Growth | 398000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.01 |
| EBITDA (p.s.) | -3.01143e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 4.73 |
| Dividend | 0 |
| Forward Dividend | 3.452e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|